• Find an Expert
  • Contact
  • SearchSearch icon
  • Menu
  • Help
  • Report an issue

Contact


Email

dale.garsed@unimelb.edu.au

Credentials


Position
Honorary Conjoint Senior Fellow
The Sir Peter MacCallum Department of Oncology
ORCID

0000-0003-1223-0121

Dr Dale Garsed

Honorary Conjoint Senior Fellow
The Sir Peter MacCallum Department of Oncology

92 Scholarly works
9 Projects

HIGHLIGHTS

  • 2026

    Journal article

    IdentifiHR predicts homologous recombination deficiency in high-grade serous ovarian carcinoma using gene expression
    DOI: 10.1038/s43856-026-01387-y
  • 2026

    Journal article

    Clinicopathologic and molecular predictors of survival in BRCA-deficient tubo-ovarian high-grade serous carcinoma
    DOI: 10.1038/s41467-026-71134-3
  • 2026

    Research grants (ARC, NHMRC, MRFF)

    Driving Cancer Discoveries Through Integration of ‘Omics and Clinical Data
  • 2024

    Research grants (ARC, NHMRC, MRFF)

    Harnessing the Immune Response in Exceptionally Long-Term Survivors of Ovarian Cancer to Develop Novel Therapeutics
  • 2020

    Research Grant

    Understanding Adverse and Exceptional Outcomes in Ovarian Cancer
  • 2015

    Journal article

    Whole-genome characterization of chemoresistant ovarian cancer
    DOI: 10.1038/nature14410
  • 2014

    Journal article

    The Architecture and Evolution of Cancer Neochromosomes
    DOI: 10.1016/j.ccell.2014.09.010
Dale Garsed

RECENT SCHOLARLY WORKS

  • 2026

    Journal article

    Using polygenic risk scores to refine risk and outcomes in high-grade serous ovarian cancer in Australia.
    DOI: 10.1158/1055-9965.EPI-25-1882
  • 2026

    Journal article

    16P Integrative proteogenomics reveals survival-linked co-expression modules and an HR activity signature in high-grade serous ovarian cancer
    DOI: 10.1016/j.esmoop.2026.108041
  • 2026

    Journal article

    Rethinking ovarian cancer III: the past decade and future directions
    DOI: 10.1038/s41568-026-00916-0
  • 2026

    Journal article

    Real-world comparative outcomes of neoadjuvant chemotherapy with interval cytoreductive surgery versus primary cytoreductive surgery in epithelial ovarian cancer: insights from the australian ovarian cancer study (AOCS)
    DOI: 10.1016/j.ijgc.2025.103076
  • 2026

    Other

    Supplementary Figure S1 from Oxford Classic–Defined EMT Risk Stratification of High-Grade Serous Ovarian Cancer for Guiding Treatment Decisions
    DOI: 10.1158/1078-0432.31006869
  • 2026

    Other

    Supplementary Figure S2 from Oxford Classic–Defined EMT Risk Stratification of High-Grade Serous Ovarian Cancer for Guiding Treatment Decisions
    DOI: 10.1158/1078-0432.31006866
  • 2026

    Other

    Supplementary Figure S5 from Oxford Classic–Defined EMT Risk Stratification of High-Grade Serous Ovarian Cancer for Guiding Treatment Decisions
    DOI: 10.1158/1078-0432.31006854
  • 2026

    Other

    Supplementary Figure S4 from Oxford Classic–Defined EMT Risk Stratification of High-Grade Serous Ovarian Cancer for Guiding Treatment Decisions
    DOI: 10.1158/1078-0432.31006857

Acknowledgement of Country

We acknowledge Aboriginal and Torres Strait Islander people as the Traditional Owners of the unceded lands on which we work, learn and live. We pay respect to Elders past, present and future, and acknowledge the importance of Indigenous knowledge in the Academy.

Read about our Indigenous priorities

About us  

Careers at Melbourne  

Safety and respect  

Newsroom  

Contact  

Campus locations  

Phone: 13 MELB ( 13 6352)

International: +61 3 9035 5511


Address:
The University of Melbourne
Grattan Street, Parkville,
Victoria, 3010, Australia

facebookIconlinkedinIconinstagramIcon

Emergency information  |  Disclaimer and copyright  |  Accessibility  |  Privacy

CRICOS number: 00116K     ABN: 84 002 705 224